Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | baculoviral IAP repeat containing 2 | No references | |
Homo sapiens | X-linked inhibitor of apoptosis, E3 ubiquitin protein ligase | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Leishmania major | chitinase | 0.0077 | 0.2004 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0122 | 1 | 1 |
Onchocerca volvulus | 0.0122 | 1 | 1 | |
Loa Loa (eye worm) | cuticular endochitinase | 0.0077 | 0.2004 | 0.2004 |
Onchocerca volvulus | 0.0114 | 0.8569 | 0.821 | |
Entamoeba histolytica | chitinase, putative | 0.0077 | 0.2004 | 0.5 |
Onchocerca volvulus | Deterin homolog | 0.0114 | 0.8569 | 0.821 |
Loa Loa (eye worm) | hypothetical protein | 0.0122 | 1 | 1 |
Onchocerca volvulus | 0.0122 | 1 | 1 | |
Loa Loa (eye worm) | hypothetical protein | 0.0114 | 0.8569 | 0.8569 |
Plasmodium falciparum | conserved protein, unknown function | 0.0122 | 1 | 0.5 |
Toxoplasma gondii | hypothetical protein | 0.0122 | 1 | 0.5 |
Brugia malayi | endochitinase | 0.0086 | 0.3645 | 0.2052 |
Plasmodium vivax | hypothetical protein, conserved | 0.0122 | 1 | 0.5 |
Brugia malayi | Inhibitor of Apoptosis domain containing protein | 0.0114 | 0.8569 | 0.821 |
Onchocerca volvulus | Putative endochitinase | 0.0086 | 0.3645 | 0.2052 |
Onchocerca volvulus | Putative endochitinase | 0.0086 | 0.3645 | 0.2052 |
Loa Loa (eye worm) | hypothetical protein | 0.0114 | 0.8569 | 0.8569 |
Brugia malayi | Inhibitor of Apoptosis domain containing protein | 0.0114 | 0.8569 | 0.821 |
Brugia malayi | Endochitinase | 0.0086 | 0.3645 | 0.2052 |
Mycobacterium ulcerans | chitinase/cellulase | 0.0066 | 0 | 0.5 |
Mycobacterium ulcerans | chitinase/cellulase | 0.0066 | 0 | 0.5 |
Echinococcus multilocularis | Hepatocellular carcinoma associated antigen 59 | 0.0122 | 1 | 1 |
Onchocerca volvulus | Putative endochitinase | 0.0086 | 0.3645 | 0.2052 |
Mycobacterium tuberculosis | Possible chitinase | 0.0066 | 0 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0122 | 1 | 1 |
Loa Loa (eye worm) | chitinase I | 0.0077 | 0.2004 | 0.2004 |
Echinococcus granulosus | Hepatocellular carcinoma associated antigen 59 | 0.0122 | 1 | 1 |
Loa Loa (eye worm) | microfilarial chitinase | 0.0075 | 0.1641 | 0.1641 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 17 nM | BindingDB_Patents: In vitro Competitive Displacement Binding Assays . Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, clAP-1 or clAP-2. BIR3 domains of clAP-1 , clAP-2 and XIAP were incubated with test compounds or SMAC based peptides and their respective peptide probes (Peptide Protein Research) in assay buffer (50mM Hepes pH 7.5, 0.025% Tween-20, 0.01 % BSA, and 1 mM DTT). Positive controls consisted of BIR3 proteins and tracer (no inhibition) and negative controls contained tracer only (100% inhibition). The samples were incubated at room temperature for 1 hr (XIAP and clAP-2) or 3hrs (clAP-1 ) prior to being read in the BMG Pherastar in Fluorescence Polarization mode (FP 485nm, 520nm, 520nm). | ChEMBL. | No reference |
IC50 (binding) | = 75 nM | BindingDB_Patents: In vitro Competitive Displacement Binding Assays. Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, clAP-1 or clAP-2. BIR3 domains of clAP-1 , clAP-2 and XIAP were incubated with test compounds or SMAC based peptides and their respective peptide probes (Peptide Protein Research) in assay buffer (50mM Hepes pH 7.5, 0.025% Tween-20, 0.01 % BSA, and 1 mM DTT). Positive controls consisted of BIR3 proteins and tracer (no inhibition) and negative controls contained tracer only (100% inhibition). The samples were incubated at room temperature for 1 hr (XIAP and clAP-2) or 3hrs (clAP-1 ) prior to being read in the BMG Pherastar in Fluorescence Polarization mode (FP 485nm, 520nm, 520nm). | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.